



PATENT
1340-1-016N

B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#18 *[Signature]*

APPLICANT : RODGER NOVAK AND ELAINE I. TUOMANEN
SERIAL NO. : 09/305,984 EXAMINER : R. ZEMAN
FILED : MAY 5, 1999 ART UNIT : 1645
DATE
ALLOWED : JULY 20, 2001 BATCH NO. : J46
FOR : NOVEL ANTIBIOTICS AND METHODS OF USING THE SAME

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to BOX ISSUE FEE, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on September 5, 2001.

Michael D. Davis, Reg. No. 39,161
(Name of Registered Rep.)

Betty Schutty 9/5/01
(Signature and Date)

TRANSMITTAL OF FORMAL DRAWINGS

BOX ISSUE FEE
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

ATTENTION: CHIEF OFFICIAL DRAFTSMAN

Dear Sir:

Subject to the approval of the Examiner in charge of this Application, please enter the attached 22 sheets of formal drawings (Figures 1-19) in place of the informal drawings submitted with the Application as originally filed. The time set for response is October 22, 2001.

Favorable action on this request is accordingly solicited.

Respectfully submitted,

Michael D. Davis
MICHAEL D. DAVIS
Attorney for Applicant(s)
Registration No. 39,161

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

Date: September 5, 2001

FIG. 1




FIG.2A

Effect of 25 aa peptide (0.1 mmol)
on growth of R6




FIG. 2B

Viability counts of R6 at OD 0.01 w/o peptide




FIG. 3

Effect of 25 aa peptide (0.1 mmol)
on growth of Lyt-4-4




FIG. 4
Titration of the 25aa peptide
effect after 4 hours




FIG. 5

Effect of 25 aa peptide on growth of R6




FIG. 6A




FIG. 6B




FIG. 7

Northern blot analysis of intergenic region




FIG. 8

Viability of A144 and R6 one hour after addition of penicillin (10xMIC), vancomycin (10xMIC) or peptide (0.4mmol)




FIG. 9

Effect of 25aa peptide (0.1mmol) on growth of clinical isolate A144




FIG.10

Effect of penicillin (10 x MIC) and peptide (0.5 mmol) on
lysis of R6 under starvation conditions




FIG. 11A

Effect of penicillin (10 x MIC) and peptide (0.5 mmol)
on lysis of F79




FIG. 11B

Effect of penicillin (10 x MIC) and peptide (0.5 mmol) on lysis of VanS/HK




FIG. 12

SSCP (single stranded conformational polymorphism) analysis
of the gene VanS/HK (type 4 and F79) of *S. pneumoniae*




FIG.13




FIG. 14




FIG. 15A




FIG. 15B




FIG.15C




FIG.16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG.19

